9 th July 2019 – Global Disposable Syringe Market research report provides a specific tool for evaluating the Industry, highlighting opportunities, and supporting strategic and tactical decision-making. This study identifies that in this rapidly-evolving and competitive environment, up-to-date marketing information is essential to monitor performance and make critical decisions for growth and development. It provides information on trends and developments, and focuses on markets capacities and on the changing structure of the Disposable Syringe. In addition, the research evaluated key market aspects, comprising capacity utilization rate, revenue, price, capacity, growth rate, gross, production, consumption, supply, export, market share, cost, import, gross margin, demand, and much more. Get a Sample Copy of This Report @ https://www.millioninsights.com/industry-reports/disposable-syringe-market-outlook/request-sample Global disposable syringe market is expected to grow a...
The
cell-free fetal DNA (cffDNA) test is a new technology being used to assess the
risk of a pregnant woman’s developing baby (fetus) against any abnormalities
such as chromosome disorder like Down sydrome (trisomy 21), Edwards syndrome
(trisomy 18) or Patau syndrome (trisomy 13). The global cell-free fetal DNA
testing market is segmented on the basis of test types and geography. This new
technology is being used as an alternative to currently available prenatal
tests. It may be used to identify other rare conditions resulting from an extra
chromosome or missing piece of chromosome (microdeletion).
This
new prenatal disorder testing technology is expected to be driven by major
factors such as safe and low risk obstetric nature of this technology for
prenatal testing coupled with increasing awareness about inherited disorders.
The two predominant prenatal tests are chorionic villus sampling (CVS) and
amniocentesis, both are invasive and could possess harm to the developing
fetus, in some cases it can cause miscarriage. Cell-free fetal DNA is a new
alternative of prenatal tests.
Browse Full Research Report @
https://www.millioninsights.com/industry-reports/cell-free-fetal-dna-cffdna-testing-market
Fetal
DNA is found in mother’s blood stream, cell-free fetal DNA enters into the
blood stream through the placenta, placenta is a flattened organ in the uterus
where maternal blood and fetal blood. The fetal DNA can be split into very
acute fragments, less than 200 base pairs on an average. Maternal DNA fragments
are also present in the blood. Fetal DNA is first noticed after 22-25 days of
fertilization and its concentrations increase as the time period of pregnancy
increases. Diagnostic tests for pregnancy using fetal DNA is possible in
seventh week of pregnancy. Fetal DNA can be rarely distinguished from the
maternal DNA through diagnostic practice.
Amniocentesis
and chorionic villus sampling prenatal test is possible within 14-20 weeks and
10-13 weeks of pregnancy respectively. Cell-free fetal DNA non-invasive test is
used to detect aneuploidy syndromes, fetal Down syndrome and signals a major
shift in diagnostic practice and prenatal screening. The primary factor for the
growth of global cell-free fetal DNA testing industry is growing awareness in
the people andrequirement of safe or low risk obstetric procedures for prenatal
testing. The technology which is used in cell-free DNA analysis and its
application to prenatal screening for aneuploidy is rapidly changing. The
growth of cell-free fetal DNA testing market is primarily attributed to
accurate and effective results for aneuploidy screening. Major factor which
limits the growth of the global cell-free fetal DNA testing market is high cost
of cell-free fetal DNA tests.
The
cell-free fetal DNA testing enables the parents to get information about
general survivable fetal aneuploidies with a high accuracy and without any
diagnostic procedure risk. In comparison with other screening method of
aneuploidy, cell-free fetal DNA testing offers various advantages such as lower
false-positive results of cell-free fetal DNA test as compared to other
screening method.
Aneuploidy
is an unusual number of chromosomes, typically characterized by the absence of
one copy of a single chromosome or by the increase in the amount of
chromosomes. The presence of an extra copy of chromosome 21 is called trisomy
21, which causes Down syndrome. On the basis of test types, the global cell-free
fetal DNA testing industry is segmented into detection of abnormal chromosome
number, paternally inherited disorders, gender testing and so on.
On
the basis of geography, the global cell-free fetal DNA testing market is
segmented into North America, Europe, Asia Pacific, Japan, Latin America and
Middle East & Africa. North America held largest share in the global market
of cell-free fetal DNA testing followed by Europe, Japan and Asia Pacific owing
to high occurrence of several diseases and increasing number of aneuploidies,
great advancement in field of aneuploidy screening and developed healthcare
infrastructure. The developing nations in Asia Pacific, Middle East and Africa
hold huge potential for growth in the global cell-free fetal DNA testing market,
due to its quick and accurate result without any risk to developing fetus.
The
key players of global cell-free fetal DNA testing market are IIIumina Inc.,
Sequenom Laboratories, Ariosa Diagnostics, Arup Laboratories, The Fetal
Medicine Centre, Apollo Path Labs, Agilent Technology, Biodesix Inc., Allenex
AB, Biocept Inc., CareD Inc., Guardant Health Inc., Inivated Limited, Natera
Inc., Quest Diagnostics, Roche Holdings AG, Sequenom Inc. and Trovagene Inc.
Request a Free Sample Copy
of This Report @ https://www.millioninsights.com/industry-reports/cell-free-fetal-dna-cffdna-testing-market/request-sample
Comments
Post a Comment